Source: China Securities Taurus APP
Acquisition of photovoltaic industry assets
Lukang Biochemical announced on the evening of July 31 that it plans to acquire 100% of the equity of Jiangxi Weike held by Wang Hong Enterprise Management Center (Limited Partnership) and Wang Meijun.
Lukang Biochemical stated that the company is optimistic about the development prospects of the photovoltaic adhesive industry and the technology and customer accumulation of the target assets to be placed in the industry. It plans to enter the adhesive industry through the asset acquisition , in order to contribute new performance growth points to listed companies.
In order to complete asset acquisition and future business development and optimize the business structure of listed companies, the company plans to sell its wholly-owned subsidiary Putan Thermal Energy to major shareholder Heli Asia, Fujie Pingtan, Beijing Kangmin or its designated entities.
is to raise the consideration for the assets that have been acquired and to introduce industrial investors to provide support for the development of new businesses of listed companies. Heli Asia (holding 26.7% of shares), Fujie Pingtan (holding 7.08% of shares), Beijing Kangmin (holding 4.95% of shares) intends to transfer to Yirui Investment (settlement 10% of shares) to Yirui Investment (settlement 10% of shares), Changxin No. 2 (settlement 10% of shares), Ciyin Investment (settlement 10% of shares) and natural person Xiao Han (settlement 6.73%). After the transfer is completed, Heli Asia's shareholding ratio dropped to 2%, and Fujie Pingtan and Beijing Kangmin no longer hold shares.
receives the exchange's attention letter
According to the announcement, the target asset Jiangxi Weike lost 6.6374 million yuan in 2021, and a loss of 6.8863 million yuan from January to April 2022, with an asset-liability ratio of 92%. The estimated value of this asset is 100 million yuan, with a premium rate of about 632%. If the final transaction price is less than RMB 95 million, the counterparty has the right to terminate the asset acquisition agreement.
The Shenzhen Stock Exchange requires GreenCon Biochemical to combine the company's main business and development strategy, the financial data and market position of the target assets to explain the reasons and necessity of the company's high premium acquisitions in the case of loss in the performance and debt-to-asset ratio of the target assets.
At the same time, the Shenzhen Stock Exchange requires that the company has sufficient capital investment capabilities and business integration capabilities based on the company's existing technology, talent reserves, market resources, etc. in the photovoltaic field, whether the company has sufficient capital investment capabilities and business integration capabilities, whether this acquisition decision is prudent and reasonable, whether it is in line with the company's development strategy, whether it can help improve the company's operating quality, and whether there is a situation of catering to hot topics to speculate on stock prices, and please once again give full reminders to the market that the investment matter may face. Independent directors are requested to express their verification opinions.
The Shenzhen Stock Exchange also requires that in light of the transactions of the company's directors, supervisors, senior management personnel, shareholders holding more than 5% of the shares and their immediate relatives in the past month, self-check whether there are insider information leakage, insider trading, etc., and explain whether relevant personnel have plans to reduce their holdings in the next 6 months.
The first half of the year's performance is expected to lose
After the acquisition plan was released, Lvkang Biochemical's stock price hit the daily limit one after another. In the announcement of stock price changes, the company pointed out that it did not find any recent public media reports that it may or has had a significant impact on the company's stock trading price. The controlling shareholder and actual controller do not buy or sell the company's stock during abnormal fluctuations in stock trading. The company and all members of the board of directors ensure that the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Lukang Biochemical expects to achieve a net profit attributable to shareholders of listed companies in the first half of 2022 to a loss of RMB 35 million to RMB 43 million, compared with a profit of RMB 6.56 million in the same period last year.The main reason for the change in
's performance is that the company's veterinary drug fundraising and investment projects and cogeneration projects have been completed and depreciation began to be accrued in the second quarter. Due to the climbing production capacity, the corresponding costs of the veterinary drug fundraising and investment projects and the cogeneration projects are relatively high, and the trial production products of the veterinary drug fundraising and investment projects are accrued with inventory impairment provisions; affected by the epidemic, logistics is poor, product sales revenue is reduced, and profits are reduced; affected by the epidemic and other factors, the prices of raw materials such as corn starch and soybean meal and coal rose sharply year-on-year, increasing the production cost of product ; due to the overseas epidemic and the rise in oil prices, the freight cost of the company's exported products has increased. The price of Jiahe Bio stocks invested by the industrial funds invested by the company has dropped compared with the same period, causing a loss in to change the fair value of .
Edited by: Wang Yin
